EXAS Exact Sciences Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXAS

Price (delayed)

$66.71

Market cap

$12.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.43

Enterprise value

$14.01B

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights
Exact Sciences's EPS has increased by 43% YoY and by 17% from the previous quarter
The company's net income rose by 41% YoY and by 16% QoQ
The company's quick ratio fell by 19% QoQ and by 5% YoY
The company's equity fell by 4.8% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.exactsciences.com/
Peers: MYGN VCYT BIOC

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
180.67M
Market cap
$12.05B
Enterprise value
$14.01B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.94
Price to sales (P/S)
5.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.09
Earnings
Revenue
$2.3B
EBIT
-$419.86M
EBITDA
-$196.49M
Free cash flow
-$83.27M
Per share
EPS
-$2.43
Free cash flow per share
-$0.46
Book value per share
$16.94
Revenue per share
$12.77
TBVPS
$11.65
Balance sheet
Total assets
$6.36B
Total liabilities
$3.3B
Debt
$2.56B
Equity
$3.06B
Working capital
$685.87M
Liquidity
Debt to equity
0.84
Current ratio
2.41
Quick ratio
1.95
Net debt/EBITDA
-9.95
Margins
EBITDA margin
-8.5%
Gross margin
73.5%
Net margin
-18.8%
Operating margin
-17.9%
Efficiency
Return on assets
-6.9%
Return on equity
-14.1%
Return on invested capital
-11.3%
Return on capital employed
-7.2%
Return on sales
-18.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
1.17%
1 week
-11.79%
1 month
-17.09%
1 year
106.28%
YTD
34.74%
QTD
-28.96%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$2.3B
Gross profit
$1.69B
Operating income
-$410.96M
Net income
-$431.68M
Gross margin
73.5%
Net margin
-18.8%
The operating margin has surged by 52% year-on-year and by 20% since the previous quarter
The company's net margin has surged by 50% YoY and by 20% QoQ
The operating income has increased by 43% year-on-year and by 17% since the previous quarter
The company's net income rose by 41% YoY and by 16% QoQ

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
3.94
P/S
5.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.09
Exact Sciences's EPS has increased by 43% YoY and by 17% from the previous quarter
The stock's price to book (P/B) is 46% less than its 5-year quarterly average of 7.2 but 8% more than its last 4 quarters average of 3.6
The company's equity fell by 4.8% YoY
EXAS's price to sales (P/S) is 56% less than its 5-year quarterly average of 11.8 but 3.2% more than its last 4 quarters average of 5.0
EXAS's revenue is up by 19% year-on-year and by 4.6% since the previous quarter

Efficiency

How efficient is Exact Sciences business performance
Exact Sciences's ROS has soared by 52% YoY and by 22% from the previous quarter
The company's return on invested capital rose by 41% YoY and by 16% QoQ
EXAS's return on assets is up by 38% year-on-year and by 16% since the previous quarter
The ROE has grown by 36% YoY and by 15% from the previous quarter

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 93% more than the total liabilities
EXAS's current ratio is down by 19% QoQ and by 2.8% YoY
The company's quick ratio fell by 19% QoQ and by 5% YoY
The company's debt is 16% lower than its equity
EXAS's debt to equity is up by 11% year-on-year
The company's equity fell by 4.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.